Cargando…
Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. Th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491361/ https://www.ncbi.nlm.nih.gov/pubmed/26108551 http://dx.doi.org/10.1007/s10637-015-0265-z |
_version_ | 1782379628692766720 |
---|---|
author | Collery, Philippe Mohsen, Ahmed Kermagoret, Anthony Corre, Samantha Bastian, Gérard Tomas, Alain Wei, Ming Santoni, François Guerra, Nadia Desmaële, Didier d’Angelo, Jean |
author_facet | Collery, Philippe Mohsen, Ahmed Kermagoret, Anthony Corre, Samantha Bastian, Gérard Tomas, Alain Wei, Ming Santoni, François Guerra, Nadia Desmaële, Didier d’Angelo, Jean |
author_sort | Collery, Philippe |
collection | PubMed |
description | Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. The Re-diselenoether showed a potent inhibitory effect on MDA-MB231 cell division in vitro, which lasted when the complex was no longer present in the culture. Re-diselenoether induced a remarkable reduction of the volume of the primitive breast tumors and of the pulmonary metastases without clinical signs of toxicity, in mice-bearing a MDA-MB231 Luc+ tumor, orthotopically transplanted, after a daily oral administration at the dose of 10 mg/kg/d. Interestingly, an antagonism was observed when cisplatin was administered as a single i.p. injection 1 week after the end of the Re-diselenoether administration. In an effort to gain insight of the mechanisms of action of Re-diselenoether complex, interaction with 9-methylguanine as a nucleic acid base model was studied. We have shown that Re-diselenoether gave both mono- and bis-guanine Re adducts, the species assumed to be responsible for the DNA intrastrand lesions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-015-0265-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4491361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-44913612015-07-08 Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer Collery, Philippe Mohsen, Ahmed Kermagoret, Anthony Corre, Samantha Bastian, Gérard Tomas, Alain Wei, Ming Santoni, François Guerra, Nadia Desmaële, Didier d’Angelo, Jean Invest New Drugs Preclinical Studies Rhenium (I)-diselenother (Re-diselenoether) is a water soluble metal-based compound, combining one atom of rhenium and two atoms of selenium. This compound has been reported to exhibit marked activities against several solid tumor cell lines. We now disclose an improved synthesis of this complex. The Re-diselenoether showed a potent inhibitory effect on MDA-MB231 cell division in vitro, which lasted when the complex was no longer present in the culture. Re-diselenoether induced a remarkable reduction of the volume of the primitive breast tumors and of the pulmonary metastases without clinical signs of toxicity, in mice-bearing a MDA-MB231 Luc+ tumor, orthotopically transplanted, after a daily oral administration at the dose of 10 mg/kg/d. Interestingly, an antagonism was observed when cisplatin was administered as a single i.p. injection 1 week after the end of the Re-diselenoether administration. In an effort to gain insight of the mechanisms of action of Re-diselenoether complex, interaction with 9-methylguanine as a nucleic acid base model was studied. We have shown that Re-diselenoether gave both mono- and bis-guanine Re adducts, the species assumed to be responsible for the DNA intrastrand lesions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10637-015-0265-z) contains supplementary material, which is available to authorized users. Springer US 2015-06-26 2015 /pmc/articles/PMC4491361/ /pubmed/26108551 http://dx.doi.org/10.1007/s10637-015-0265-z Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Preclinical Studies Collery, Philippe Mohsen, Ahmed Kermagoret, Anthony Corre, Samantha Bastian, Gérard Tomas, Alain Wei, Ming Santoni, François Guerra, Nadia Desmaële, Didier d’Angelo, Jean Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title | Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title_full | Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title_fullStr | Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title_full_unstemmed | Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title_short | Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer |
title_sort | antitumor activity of a rhenium (i)-diselenoether complex in experimental models of human breast cancer |
topic | Preclinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491361/ https://www.ncbi.nlm.nih.gov/pubmed/26108551 http://dx.doi.org/10.1007/s10637-015-0265-z |
work_keys_str_mv | AT colleryphilippe antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT mohsenahmed antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT kermagoretanthony antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT corresamantha antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT bastiangerard antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT tomasalain antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT weiming antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT santonifrancois antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT guerranadia antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT desmaeledidier antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer AT dangelojean antitumoractivityofarheniumidiselenoethercomplexinexperimentalmodelsofhumanbreastcancer |